特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
921904

世界のクラミジア感染症診断市場:成長、動向、および予測(2020年~2025年)

Chlamydia Infection Diagnostics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.37円
世界のクラミジア感染症診断市場:成長、動向、および予測(2020年~2025年)
出版日: 2020年06月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のクラミジア感染症断市場は、クラミジアの流行と従来の技術から分子診断への主な移行により、急速に成長しています。また、臨床検査ベースの検査は、同市場のシェアを大きく占めており、中でも、クラミジアトラコマチスの遺伝物質であるDNAを検出する分子検査である核酸増幅検査(NAAT)が推奨されています。さらに、新しい診断ツールに関しては、薬やワクチンよりもわずかなコストで非常に短い時間で開発でき、今後の市場機会の一つに挙げられます。

当レポートは世界のクラミジア感染症断市場について調査しており、市場機会や動向、成長および阻害要因、検査タイプ・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • クラミジアの発生率の上昇と有病率の増加
    • 迅速なテストに対する需要の増加
  • 市場阻害要因
    • 専門のSTDクリニックを訪れる患者に関する社会的スティグマ
    • 医療へき地での大勢のクラミジア感染患者
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • テストタイプ別
    • 文化試験
    • 核酸増幅試験(NAAT)
    • 直接蛍光抗体法
    • 血清検査
    • その他
  • エンドユーザー別
    • 病院
    • 診断センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • BIO-RAD LABORATORIES
    • Danaher Corporation (Cepheid)
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc.
    • QUIDEL CORPORATION
    • SAVYON DIAGNOSTICS
    • TRINITY BIOTECH

第7章 市場機会および今後の動向

目次
Product Code: 67399

The Chlamydia Infection Diagnostics Market is found increasing due to the increasing prevalence rates of chlamydia and the growing demand for rapid testing.

Owing to the rising prevalence of chlamydia and major shift from conventional technologies to molecular diagnostics the market studied is growing rapidly. In 2016, WHO estimated 376 million new infections with 1 of 4 being STIs, out of which the incidence of chlamydia was 127 million, gonorrhea was 87 million, and syphilis was 6.3 million. Furthermore, there is a growing focus on rapid testing since it delivers quick results.

In 2018, the NIBIB-funded researchers authorized a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby curtailing the further spread of disease. There is a negative social perception of STDs, as they are caused due to sexual interactions. Hence, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.

Key Market Trends

Nucleic Acid Amplification Test (NAAT) Based Tests is Found Dominates the Chlamydia Infection Diagnostics Market

The Nucleic Acid Amplification Test (NAAT) is found to be the most recommended method. It is a molecular test that detects DNA, the genetic material of Chlamydia trachomatis. The method is usually more sensitive and specific than the other chlamydia tests and it can be performed on a vaginal swab taken from women, as well as on urine from both men and women, and thus it eliminates the requirement for a pelvic exam in women.

Most of the time, NAATs can be used with both urine and vaginal samples for women. However, only some are approved for use with samples taken from men as well. Furthermore, new diagnostic tools can be developed for a fraction of the cost and in much less time than either a drug or a vaccine which suggests that focused funding and effort should be able to produce viable tools in a relatively short period of time.

North America is Expected to Dominate the Chlamydia Infection Diagnostics Market

North America is found holding a leading position in the Chlamydia Infection Diagnostics market during the forecast period. In 2017, a total of 1,708,569 chlamydial infections were reported to the Centre for Disease Prevention and Control (CDC) in 50 states of the United States. During 2016-2017, the rate of reported cases increased by 6.9%, from 494.7 to 528.8 cases per 100,000 population.

The National Health and Nutrition Examination Survey (NHANES) is a nationally representative survey of the US civilian, a non-institutionalized population that provides an important measure of chlamydia disease burden in respondents aged 14-39 years. In March 2019, USFDA granted clearance to diagnostic tests for extragenital testing for chlamydia and gonorrhea, Aptima Combo 2 Assay, to Hologic Inc. and Xpert CT/NG to Cepheid. Hence, the high rate of diagnosis, high adoption, and awareness among the people and the introduction of new and technologically advanced tests are also contributing to the growth of the market in North America.

Competitive Landscape

Currently, many private pharmaceuticals and biotechnology companies drive, direct, and coordinate the development and introduction of novel products into the market which are easily affordable and accessible. Some of the key innovations in the market include in July 2019, Nurx, the San Francisco-based startup launched three new test kits, which will test for conditions such as chlamydia, gonorrhea, and syphilis.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence Rate of Chlamydia Infection
    • 4.2.2 Growing Demand for Rapid Testing
  • 4.3 Market Restraints
    • 4.3.1 Social Stigma Associated with Patients Visiting Specialized STD Clinics
    • 4.3.2 Huge Proportion of Patients Infected with Chlamydia in Out-of-reach Geographic Areas
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Culture Tests
    • 5.1.2 Nucleic Acid Amplification Test (NAAT)
    • 5.1.3 Direct Fluorescent Antibody Test
    • 5.1.4 Serology Tests
    • 5.1.5 Others
  • 5.2 End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Bio-Rad Laboratories, Inc.
    • 6.1.4 Danaher Corporation (Cepheid)
    • 6.1.5 DiaSorin SpA
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Hologic, Inc.
    • 6.1.8 Quidel Corporation
    • 6.1.9 Savyon Diagnostics Ltd.
    • 6.1.10 Trinity Biotech Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.